Usefulness of rCBF analysis in diagnosing Parkinson’s disease: supplemental role with MIBG myocardial scintigraphy
- 123 Downloads
123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is a useful tool for differentiating idiopathic Parkinson’s disease (PD) from parkinsonism (PS) caused by other disorders. However, cardiac MIBG uptake is affected by various causes. Alternatively, hypoperfusion in the occipital lobe of PD is reported recently.
The objective is to clarify the correlation between regional cerebral blood flow (rCBF) alteration and cardiac MIBG uptake in PD. In addition, we examined whether additional brain perfusion analysis improved the differential diagnostic ability for PD from PS when compared with MIBG scintigraphy alone.
Forty-nine patients with PD (27 mild groups: Hoehn and Yahr stages I, II; 22 severe groups: Hoehn and Yahr stages III, IV) and 28 patients with PS participated. We compared absolute rCBF values between PD and PS. In addition, we determined correlation between MIBG parameters and each rCBF value. Finally, we compared the diagnostic ability for the differentiation of PD from PS between two diagnostic criteria, each MIBG index abnormality alone [heart-to-mediastinum ratio, H/M (E) < 1.9, H/E (D) < 1.7, washout rate > 40%] and each MIBG index abnormality or occipital lobe hypoperfusion (<36 ml/100 g per min).
Absolute rCBF value of occipital lobe was significantly lower in severe PD as compared with PS or mild PD. In the correlation analysis, rCBF of occipital lobe correlated positively with MIBG parameters (H/M). Regarding the diagnostic ability, sensitivity improved by accounting for occipital hypoperfusion as compared with MIBG indices alone. In contrast, neither specificity nor accuracy improved by adding occipital lobe analysis.
MIBG parameters (H/M) correlated positively with occipital hypoperfusion in PD. In the differential diagnosis between PD and PS, although its usefulness might be limited, analysis of rCBF in the occipital lobe added to 123I-MIBG myocardial imaging can be recommended.
Keywords123I-MIBG 99mTc-HMPAO 3D-SSP 3D-SRT Parkinson’s disease
Unable to display preview. Download preview PDF.
- 19.Sakai T, Kuzuhara S. Correlation of the cognitive function and the duration of the illness with the regional cerebral blood flow in the patients with Parkinson’s disease: objective evaluation using stereotactic extraction estimation analysis in 123I-IMP SPECT (in Japanese). No To Shinkei 2006;58:29–37.PubMedGoogle Scholar
- 24.Van Laere K, Santens P, Bosman T, Reuck JD, Mortelmans L, Dierckx R. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson’s disease and multiple system atrophy with predominant parkinsonian features: correlations with clinical parameters. J Nucl Med 2004;45:933–942.PubMedGoogle Scholar
- 33.Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J Neurosci 1998;155:60–67.Google Scholar
- 36.Arahata Y, Kato T, Ito K, et al. PET and SPECT studies in Parkinson’s disease with dementia. Cogn Dement 2004;3:45–49.Google Scholar
- 37.Ito K, Morrish PK, Rakshi JS, Uema T, Ashburner J, Bailey DL, et al. Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease. J Neurosurg 1999;66:754–758.Google Scholar
- 40.Ito H, Inoue K, Goto R, Kinomura S, Taki Y, Okada K, et al. Database of normal human cerebral blood flow measured by SPECT: I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxel-based morphometry. Ann Nucl Med 2006;20:131–138.PubMedCrossRefGoogle Scholar
- 44.Fukuda H. Brain morphology and function: recent development in neuroimaging. 1st ed. Tokyo: Shinko Igaku; 2005. p. 117–127.Google Scholar